Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both β2- and β3-adrenergic receptors by Nackley, Andrea Gail et al.
Catechol-O-methyltransferase Inhibition Increases Pain
Sensitivity through Activation of Both β2 and β3 Adrenergic
Receptors
Andrea Gail Nackley-Neely1, Kai Soo Tan2, Karamarie Fecho3, Patrick Flood2, Luda
Diatchenko1, and William Maixner1
1 Center for Neurosensory Disorders, School of Dentistry, University of North Carolina, Chapel Hill, NC,
27599-7450 USA
2 Comprehensive Center for Inflammatory Disorders, School of Dentistry, University of North Carolina,
Chapel Hill, NC, 27599-7455 USA
3 Division of Pain Medicine, Department of Anesthesiology, School of Medicine, University of North Carolina,
Chapel Hill, NC, 27599-7010 USA
Abstract
Catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines, has recently
been implicated in the modulation of pain. Our group demonstrated that human genetic variants of
COMT are predictive for the development of Temporomandibular Joint Disorder (TMJD) and are
associated with heightened experimental pain sensitivity (Diatchenko et al. 2005). Variants
associated with heightened pain sensitivity produce lower COMT activity. Here we report the
mechanisms underlying COMT-dependent pain sensitivity. To characterize the means whereby
elevated catecholamine levels, resulting from reduced COMT activity, modulate heightened pain
sensitivity, we administered a COMT inhibitor to rats and measured behavioral responsiveness to
mechanical and thermal stimuli. We show that depressed COMT activity results in enhanced
mechanical and thermal pain sensitivity. This phenomenon is completely blocked by the nonselective
β-adrenergic antagonist propranolol or by the combined administration of selective β2- and β3-
adrenergic antagonists, while administration of β1-adrenergic, α-adrenergic, or dopaminergic
receptor antagonists fail to alter COMT-dependent pain sensitivity. These data provide the first direct
evidence that low COMT activity leads to increased pain sensitivity via a β2/3-adrenergic mechanism.
These findings are of considerable clinical importance, suggesting that pain conditions resulting from
low COMT activity and/or elevated catecholamine levels can be treated with pharmacological agents
that block both β2- and β3-adrenergic receptors.
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Catecholamines and enzymatic pathways that regulate the bioavailability of catecholamines
influence persistent pain. Adrenergic systems contribute to the pathogenesis of rheumatoid
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arthritis in animals, as denervation of sympathetic noradrenergic fibers (Levine et al. 1986a)
and depletion of peripheral epinephrine (Coderre et al. 1990) attenuate arthritic responses.
Additionally, chronic administration of β-adrenergic receptor (βAR) agonists produces a
painful arthritis-like syndrome (Vyden et al. 1971). These findings are consistent with clinical
observations that sympathetic blockade or administration of the βAR antagonist propranolol
reduces the severity of arthritis and joint responses to injury (Baerwald et al. 1997;Kaplan et
al. 1980;Levine et al. 1986b).
A sustained elevation in catecholamines is also associated with common chronic
musculoskeletal pain conditions. Fibromyalgia patients have higher basal norepinephrine
levels and exaggerated norepinephrine responses to interleukin-6 (Torpy et al. 2000).
Additionally, individuals with myofacial pain conditions have higher catecholamine levels and
augmented sympathetic responses to stressors (Evaskus and Laskin 1972;Perry et al. 1989).
As with arthritis, βAR antagonists provide significant pain relief for patients with fibromyalgia
(Wood et al. 2005) and TMJD (Bhalang et al. 2004).
Abnormalities in catecholamine physiology are associated with diminished activity of
catechol-O-methyltransferase (COMT), a ubiquitously expressed enzyme that metabolizes
catecholamines (epinephrine, norepinephrine, and dopamine) L-dopa, catecholestrogens,
ascorbic acid, and dihydroxyindolic intermediates of melanin (Mannisto and Kaakkola 1999).
Facial pain patients exhibit lower COMT activity relative to controls (Marbach and Levitt
1976). Furthermore, functional polymorphisms in the COMT gene resulting in 3- to 15-fold
reductions in COMT activity (Lotta et al. 1995;Nackley et al. 2005a) are associated with
fibromyalgia (Gursoy et al. 2003), TMJD onset (Diatchenko et al. 2005), experimental pain
sensitivity (Diatchenko et al. 2005;Zubieta et al. 2003), and morphine efficacy in cancer pain
treatment (Rakvag et al. 2005). Collectively, these results suggest that elevated catecholamime
levels promote persistent pain states.
To characterize the means whereby elevated catecholamine levels, resulting from reduced
COMT activity, modulate pain sensitivity, we administered a COMT inhibitor to rats and
measured behavioral responsiveness to mechanical and thermal stimuli. The degree of pain
sensitivity produced by COMT inhibition was compared to that produced by intraplantar
carrageenan, an inflammatory agent that causes sensitization of peripheral and central neurons
and results in increased pain sensitivity to noxious (hyperalgesia) and normally innocuous
stimuli (allodynia) (Cooper 1993;Hedo et al. 1999). The carrageenan model of inflammatory
pain produces a well-characterized increase in pain sensitivity, allowing for assessment of
potential analgesics (Kehl and Fairbanks 2003;Kocher et al. 1987;Stanfa and Dickenson
1995). Thus, we used this model as a standard for estimating the extent of COMT inhibitor
effects on pain.
Here we show that depressed COMT activity results in profound increases in mechanical and
thermal pain sensitivity, similar to that produced by intraplantar carrageenan. This enhanced
sensitivity to noxious stimuli is blocked by the nonselective βAR antagonist propranolol or by
combined administration of selective β2- and β3AR antagonists. Our findings provide evidence
for a novel animal model that mimics the persistent pain observed in TMJD and fibromyalgia
patients and elucidates the key importance of β-adrenergic pathways in pain states associated
with reduced COMT activity.
Materials and Methods
Subjects
Two-hundred and twenty-eight adult male Sprague-Dawley rats (250–320g; Charles River
Laboratories, Raleigh, NC) were used in these experiments. All procedures were approved by
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the University of North Carolina Animal Care and Use Committee and adhered to the
guidelines of the Committee for Research and Ethical Issues of the IASP (Zimmermann
1983).
Drugs and Chemicals
OR486 and RO41-0960 were dissolved in dimethylsulfoxide (DMSO) and diluted in 0.9%
saline pH 7.5 (3:2). Phentolamine, propranolol, SCH23390, and spiperone were dissolved in
ethanol and diluted in 0.9% saline pH 3.5 (1:4). Betaxolol, ICI118,551, and SR59230A were
dissolved in DMSO and diluted in 0.9% saline (1:4). Lambda carrageenan (3%) was dissolved
in 0.9% saline and administered in a volume of 100 μl. OR486, RO41-0960, phentolamine,
propranolol, and carrageenan were obtained from Sigma Aldrich (St. Louis, MO), while
SCH23390, betaxolol, ICI118,551, SR59230A, salmeterol, and CL316243 were purchased
from Tocris (Ellisville, MO).
General Experimental Methods
Rats were handled and habituated to the testing environment 2 – 3 days prior to establishing
baseline responsiveness to mechanical and thermal stimuli. On test days, rats were placed in
plexiglass cages positioned over an elevated perforated stainless steel platform and habituated
to the environment for 15 – 20 min prior to testing. After stable baseline measures were
obtained, pharmacological manipulations were performed and behavior reassessed.
In the first study, separate groups of rats received an intraperitoneal (i.p.) injection of the COMT
inhibitor OR486 or RO41-0960 or vehicle. In subsequent studies designed to establish which
receptors mediate COMT-dependent pain behavior, separate groups of rats received i.p.
injections of antagonist or vehicle 10 min prior to i.p. administration of OR486 or vehicle.
Behavioral responses to mechanical stimuli were reassessed every 30 min over a 2 hr time
period and responses to thermal stimuli were reassessed at 2.25 hrs following administration
of the COMT inhibitor. In all studies, the experimenter was blind to the experimental condition.
Generation of Inflammation-induced Hyperalgesia
Ten min following i.p. administration of the COMT inhibitor OR486 or vehicle, rats received
a unilateral intraplantar (i.pl.) injection of carrageenan (3%, 100 μl) or saline. Behavioral
responses to mechanical stimuli were reassessed every 30 min over a 2 hr time period and
responses to thermal stimuli were reassessed at 2.25 hrs following carrageenan administration.
Time points were selected based on previous work showing that the development of
carrageenan-induced hindpaw edema is composed of an early phase beginning immediately
and lasting 20–60 min post-injection and a late phase which is maximal 2–3 hrs post injection
(Doherty and Robinson 1975).
Assessment of Tactile Allodynia and Mechanical Hyperalgesia
Tactile allodynia was assessed using the up-down method (Chaplan et al. 1994) to determine
the threshold for paw withdrawal to punctate mechanical stimulation. A series of nine calibrated
filaments (with bending forces of 0.40, 0.68, 1.1, 2.1, 3.4, 5.7, 8.4, 13.2, and 25.0 g; Stoelting)
with approximately equal logarithmic spacing between stimuli (Mean ± SEM: 0.232 ± 0.04
units) were presented to the hind paw in successive order, whether ascending or descending.
Filaments were positioned in contact with the hindpaw for a duration of 3 s or until a withdrawal
response occurred. Testing was initiated with the middle hair of the series (3.4 g). In the absence
of a paw withdrawal response, an incrementally stronger filament was presented and in the
event of a paw withdrawal, an incrementally weaker filament was presented. After the initial
response threshold was crossed, this procedure was repeated in order to obtain a total of six
responses in the immediate vicinity of the threshold. The pattern of withdrawals (X) and
Nackley-Neely et al. Page 3













absence of withdrawals (O) was noted together with the terminal filament used in the series of
six responses. The 50% g threshold = (10[Xf + kδ])/10,000, where Xf = value (in log units) of
the final von Frey hair used; k = tabular value of pattern of positive (X) and negative (O)
responses, and δ = mean difference (in log units) between stimuli.
Immediately following determination of the response threshold, paw withdrawal frequency
(%) to punctate mechanical stimulation was assessed. A von Frey monofilament with a
calibrated bending force of 25 g was presented to the hind paw ten times for a duration of 1 s
with an interstimulus interval of approximately 1 s. Mechanical hyperalgesia was defined as
an increase in the percentage frequency ([# of paw withdrawals/10] x 100) of paw withdrawal
evoked by stimulation with von Frey monofilaments.
Assessment of Thermal Hyperalgesia
Thermal hyperalgesia was evaluated using the radiant heat method (Hargreaves et al. 1988) in
the same animals evaluated for responsiveness to von Frey monofilaments. Radiant heat was
presented through the floor of the stainless steel platform to the midplantar region of the hind
paw. Stimulation was terminated upon paw withdrawal or after 20 s if the rat failed to withdraw
from the stimulus. Paw withdrawal latencies to the thermal stimulus were recorded in triplicate.
Statistical Analysis
All 50% paw withdrawal threshold data sets passed the D’Angostino-Pearson omnibus
normality test, verifying that the data were sampled from a Gaussian population. Thus,
mechanical behavioral data were analyzed by analysis of variance (ANOVA) for repeated
measures or paired t-test where appropriate. Thermal behavioral data were analyzed by
ANOVA or paired t-test. Post hoc comparisons were performed using the Bonferroni test. P <
0.05 was considered to be statistically significant.
Results
COMT Inhibition Increases Pain Sensitivity
To evaluate the effects of depressed levels of COMT on pain behavior, the COMT inhibitor
OR486 or RO41-0960 was administered to separate groups of rats and their effects on tactile
allodynia, mechanical hyperalgesia, and thermal hyperalgesia were determined. As OR486 and
RO41-0960 have distinct chemical structures, their effects on pain sensitivity can be attributed
directly to COMT inhibition. Behavioral responsiveness to mechanical and thermal stimuli did
not differ between groups prior to pharmacological manipulations. I.p. administration of the
COMT inhibitor OR486 (30 mg/kg) or RO41-0960 (30 mg/kg) produced tactile allodynia
(F2,6 = 253.6, P < 0.0001; Fig. 1A), mechanical hyperalgesia (F2,6 = 120.1, P < 0.0001; Fig.
1B), and thermal hyperalgesia (F2,21 = 33.14, P < 0.0001; Fig. C) compared to administration
of vehicle. COMT-dependent increases in pain sensitivity were observed 30 min following
drug administration and lasted throughout the duration of the experimental procedure.
In order to evaluate the degree of pain sensitivity produced by COMT inhibition, the COMT
inhibitor OR486 was administered to rats and its effects on pain behavior were compared to
those produced in a classic inflammatory pain model. Separate groups of rats received i.p.
injections of the COMT inhibitor OR486 (30 mg/kg) or vehicle 10 min prior to i.pl. carrageenan
(3%) or saline. Compared to animals receiving vehicle + saline, those receiving OR486 + saline,
vehicle + carrageenan, or OR486 + carrageenan exhibited tactile allodynia (F3,9 = 268.6, P <
0.0001; Fig. 1D), mechanical hyperalgesia (F3,9 = 44.78, P < 0.0001; Fig. 1E), and thermal
hyperalgesia (F3,28 = 49.02, P < 0.0001; Fig. 1F). The degree of allodynia and hyperalgesia
produced by OR486 was remarkable as it was comparable to that produced by intraplantar
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carrageenan. Behavioral responsiveness to mechanical and thermal stimuli did not significantly
differ between animals receiving vehicle + carrageenan or OR486 + saline.
Additionally, administration of OR486 augmented carrageenan-induced pain sensitivity.
Administration of OR486 + carrageenan produced significantly greater tactile allodynia and
mechanical hyperalgesia relative to all comparison groups. The additive effects of OR486 +
carrageenan versus vehicle + carrageenan and OR486 + saline on tactile allodynia (F2,6 = 23.78,
P < 0.002) and mechanical hyperalgesia (F2,6 = 23.19, P < 0.002) are summarized in the Fig.
1D inset and Fig. 1E inset, respectively. Administration of OR486 + carrageenan also produced
significantly greater thermal hyperalgesia relative to administration of OR486 + saline (F3,28
= 49.02, P < 0.0001; Fig. 1F).
The Nonselective βAR Antagonist Propranolol Completely Blocks COMT-dependent
Increases in Pain Sensitivity
COMT acts peripherally and centrally to metabolize epinephrine, norepinephrine, and
dopamine. Thus, pharmacological methods were used to establish which receptor class
mediates the COMT-dependent increases in pain behavior. Separate groups of rats received
i.p. injections of the αAR antagonist phentolamine (3 mg/kg), the βAR antagonist propranolol
(3 mg/kg), the D1-like DAR antagonist SCH23390 (0.2 mg/kg), the D2-like DAR antagonist
spiperone (0.2 mg/kg), or vehicle 10 min prior to i.p. administration of OR486. Doses of
adrenergic (Hord et al. 2001;Kim et al. 1993;Lee et al. 1997;Safieh-Garabedian et al.
2002;Tonussi and Ferreira 1992) and dopaminergic (Hu and Jin 1999;Krowicki 1991) receptor
antagonists were selected based on the ability of comparable doses to produce analgesia in
other rat models. The development of OR486-induced increase in pain sensitivity was
completely blocked by the β-adrenergic antagonist propranolol, which attenuated the
development of tactile allodynia (F5,15 = 305.9, P < 0.0001; Fig. 2A), mechanical hyperalgesia
(F5,15 = 93.96, P < 0.0001; Fig. 2B), and thermal hyperalgesia (F5,42 = 24.47, P < 0.0001; Fig.
2C) relative to animals receiving phentolamine, SCH23390, spiperone, or vehicle prior to
OR486. The αAR, D1-like DAR, and D2-like DAR antagonists failed to block the effects of
OR486. Antagonists administered in the absence of OR486 did not alter pain sensitivity (Fig.
2D–F). These results provide strong evidence for β-adrenergic signaling in COMT-dependent
hyperalgesia, while evidence for α-adrenergic and dopaminergic signaling was not observed.
Selective β2- or β3AR Antagonists Partially Block COMT-dependent Increases in Pain
Sensitivity
Propranolol is a nonselective βAR antagonist. Doses similar to that used in the present study
block activity of β1- and β2ARs (O'Donnell et al. 1994) and reduce the activity of β3ARs
(Tsujii and Bray 1998). Thus additional studies were conducted in order to identify the βAR
subtype(s) that mediate the development of OR486-induced increases in pain sensitivity. Rats
received i.p. injections of the β1 antagonist betaxolol (0.1, 1.0, or 10 mg/kg), the β2 antagonist
ICI118,551 (0.05, 0.5, or 5 mg/kg), the β3 antagonist SR59230A (0.5, 5, or 50 mg/kg), or
vehicle 10 min prior to i.p. administration of OR486. Administration of the β2AR antagonist
ICI118,551 or the β3AR antagonist SR59230A, but not the β1AR antagonist betaxolol, reduced
the heightened pain sensitivity produced by OR486 in a dose-dependent fashion (Fig. 3).
Administration of the middle or high dose of ICI118,551 prior to OR486 partially blocked the
development of tactile allodynia (F4,12 = 281.2, P < 0.0001; Fig. 3A) and mechanical
hyperalgesia (F4,12 = 87.61, P < 0.0001; Fig. 3B), while the high dose of ICI118,551 was
necessary to partially block thermal hyperalgesia (F4,25 = 9.87, P < 0.0001; Fig. 3C).
Administration of the middle or high dose of SR59230A prior to OR486 partially blocked the
development of tactile allodynia (F4,12 = 151.4, P < 0.0001; Fig. 3D), mechanical hyperalgesia
(F4,12 = 104.6, P < 0.0001; Fig. 3E), and thermal hyperalgesia (F4,25 = 10.65, P < 0.0001; Fig.
3F). It is important to note that no differences in COMT-dependent pain sensitivity were
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observed between animals receiving the middle and high dose of ICI118,551 or between
animals receiving the middle and high dose of SR59230A. Administration of betaxolol prior
to OR486 failed to affect tactile allodynia (Fig. 3G), mechanical hyperalgesia (Fig. 3H), or
thermal hyperalgesia (Fig. 3I). Selective βAR antagonists administered in the absence of
OR486 did not alter pain sensitivity (Fig. 3J–L).
Coadministration of both β2- and β3AR Antagonists Blocks COMT-dependent Increases in
Pain Sensitivity
Administration of β2- or β3AR antagonists reduced the development of increased pain
sensitivity produced by COMT inhibition; however, only a partial blockade of OR486-induced
increased pain sensitivity was achieved. These results suggest that while β2- and β3ARs
independently contribute to COMT-dependent pain sensitivity, their combined activation is
necessary to produce the maximum degree of COMT-dependent pain sensitivity. To test this
hypothesis, ICI118,551 and SR59230A were administered together prior to administration of
OR486. Coadministration of β2- and β3AR antagonists completely blocked the development
of OR486-induced tactile allodynia (t3 = 23.69, P < 0.0003; Fig. 4A), mechanical hyperalgesia
(t3 = 42.77, P < 0.0001; Fig. 4B), and thermal hyperalgesia (t7 = 10.60, P < 0.0001; Fig. 4C).
Discussion
COMT Inhibition Increases Pain Behavior via β2 and β3 Adrenergic Receptors
COMT inhibition results in a remarkable enhancement of mechanical and thermal pain
sensitivity, comparable to that produced by carrageenan, a chemical well known for its ability
to sensitize nociceptors and increase pain behavior (Hedo et al. 1999). Furthermore, COMT
inhibition augments carrageenan-induced pain sensitivity. COMT-dependent increases in pain
sensitivity are completely blocked by the nonselective β-adrenergic antagonist propranolol or
by the combined administration of selective β2- and β3-adrenergic antagonists. Administration
of β2- or β3AR antagonists alone prior to OR486 produce only a partial blockade of enhanced
pain sensitivity, thus suggesting that COMT-dependent pain sensitivity is mediated through
coincident β2/3-adrenergic signaling processes.
Our findings elucidate the key importance of β2/3-adrenergic pathways in the development of
pain states resulting from reduced COMT activity. β2ARs are predominantly located on
vascular, uterine, and airway smooth muscle (Dixon et al. 1986) and mononuclear leukocytes
in the periphery (Landmann 1992) as well as cerebellar and thalamic neurons (Nicholas et al.
1996;Rainbow et al. 1984) and glial cells (Salm and McCarthy 1992;Stone and Ariano 1989)
in the central nervous system. Moderate levels of expression have also been observed in
adipocytes (Kobilka et al. 1987) and spinal dorsal horn neurons (Nicholson et al. 2005). The
contribution of β2ARs to enhanced pain sensitivity is in line with results from previous studies
demonstrating that epinephrine activates β2ARs located on primary afferent nociceptors and
produces a hyperalgesic state in rats (Aley et al. 2001;Khasar et al. 1999a;Khasar et al.
1999b;Khasar et al. 2003). Additionally, common variants of the human β2AR gene, coding
for differences in receptor expression and internalization, are associated with the development
of TMJD (Diatchenko et al. 2006). Furthermore, there is evidence that β2ARs play a functional
role in the development of opioid-induced hyperalgesia, a syndrome characterized by increased
sensitivity to noxious stimuli following acute and chronic opioid administration (Liang et al.
2006;Nackley et al. 2006). Our findings together with this work suggest that the alterations in
COMT-dependent pain sensitivity and μ-opioid responses observed by Zubieta and colleagues
(2003) may also be influenced by β2-adrenergic receptor stimulation.
The contribution of β3ARs is particularly novel as this is the first demonstration that they
mediate the development of pain. Until now, β3ARs, which are mainly expressed in brown and
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white adipose tissue, have been primarily known for their ability to regulate norepinephrine-
induced changes in energy metabolism and thermogenesis (Strosberg 1997). β3ARs are unique
in that they do not undergo desensitization (Cao et al. 2000;Liggett et al. 1993); thus, their
activation and the stimulation of downstream effectors likely continue for prolonged periods.
Collectively, these findings suggest that suppressing β2/3-adrenergic systems will attenuate
pain by reducing the activity of catecholamines that engage peripheral and/or central processes
to promote mechanical allodynia and thermal hyperalgesia.
The present work employed an animal model of pain behavior designed to mimic human
persistent pain conditions associated with diminished COMT activity. Although our findings
elucidate the importance of β2/3ARs in the development of acute COMT-dependent pain
sensitivity, sustained administration of a COMT inhibitor is necessary to characterize the role
of β2/3ARs in the development of persistent pain conditions associated with prolonged
reductions in COMT activity. Additional studies are also required to elucidate the role of
peripheral versus central β2/3-adrenergic systems in the development of COMT-dependent pain
sensitivity. Although epinephrine and norepinephrine have previously been shown to sensitize
nociceptors located on small diameter primary afferents in the periphery (Hu and Zhu
1989;Khasar et al. 1999b;Shyu et al. 1989), elevated levels of central catecholamines are
generally associated with descending inhibition of pain via actions at α2ARs or D2DARs in
the spinal dorsal horn (Millan 2002). Antidepressants used extensively in the treatment of
persistent pain conditions, are thought to inhibit pain transmission at the spinal level by
increasing synaptic levels of norepinephrine and serotonin (Sanchez and Hyttel 1999) as well
as by blocking tetrodotoxin-resistant sodium channels (Brau et al. 2001). Furthermore,
catecholamine-induced elevations in blood pressure have been shown to produce analgesia
through the stimulation of arterial baroreceptors (Maixner and Randich 1984;Randich and
Maixner 1984;Zamir and Maixner 1986). Taken together, these findings are in line with the
view that catecholamines can exert divergent influences on nociception as a function of
localization and net influence on neuronal excitability. The bidirectional role of a single
transmitter can be explained in part by diversity in receptor heterodimerization and second
messenger systems. As catecholamines engage different receptor signaling networks in
different animal pain models and clinical pain conditions, future studies are required to identify
the anatomical sites and signaling mechanisms whereby β2- and β3ARs mediate COMT-
dependent pain sensitivity.
Potential Signaling Mechanisms Whereby β2/3 Receptors Mediate Pain Sensitivity
Both β2- and β3ARs belong to the superfamily of G protein-coupled receptors and couple to
Gs to stimulate adenylyl cyclase (Dixon et al. 1986;Strosberg 1997) or to Gi/s to stimulate the
mitogen-activated protein kinase (MAPK) cascade (Daaka et al. 1997;Schmitt and Stork
2000;Soeder et al. 1999). Recent studies have also identified a novel Gi/s-independent
mechanism whereby β2- and β3ARs activation can stimulate extracellular signal-regulated
kinase (ERK; a type of MAPK) through a novel Gi/s-independent mechanism (Azzi et al.
2003;Cao et al. 2000). Activation of β2ARs located on nociceptors has been shown to increase
pain sensitivity via Gs/adenylyl cyclase-driven protein kinase A- and protein kinase C-
dependent pathways or via Gi/MAPK-dependent pathways (Aley et al. 2001;Khasar et al.
1999a;Khasar et al. 1999b). Upon stimulation, MAPKs regulate pain sensitivity through both
transcriptional and non-transcriptional means (Obata and Noguchi 2004).
Within recent years it has become increasingly recognized that proinflammatory mediators,
including cytokines (e.g., TNFα, IL-1β, and IL-6), prostaglandins, and reactive oxygen species,
also play an important role in mediating pain sensitivity (Burysek and Houstek 1997;Kress
2004;Maimone et al. 1993;Marchand et al. 2005;Sommer and Kress 2004). Activation of
β2ARs on cells in the periphery (Frost et al. 2004) or central nervous system (Maimone et al.
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1993) promotes the synthesis and release of IL-6. Additionally, activation of β3ARs on
adipocytes stimulates IL-6 transcription (Burysek and Houstek 1997). We have extended these
findings in a recent study showing that systemic COMT inhibition increases circulating plasma
levels of TNFα, IL-1β, and IL-6 in rat in a β2- and β3AR-dependent manner (Nackley et al.
2005b). Once these proinflammatory cytokines are synthesized and released, they can activate
and sensitize nociceptors via direct receptor-mediated actions or through the recruitment of
additional mediators (Kress 2004;Sommer and Kress 2004). Importantly there is emerging
evidence that stimulation of MAPKs induces the transcription of TNFα, IL-1β, and IL-6 (Chi
et al. 2004;Koj 1996). Moreover, a recent report demonstrates that β2ARs located on
macrophages leads to IL-1β and IL-6 production through ERK1/2- and p38-dependent
activation of ATF-1 and ATF-2 transcription factors (Tan et al. 2006). Thus, β2/3AR-mediated
increases in protein kinase stimulation and proinflammatory cytokine production are not
independent processes. Further studies are required to identify the cellular pathways through
which β2- and β3AR stimulation increases pain sensitivity.
Conclusions and Implications
Taken together, these data provide evidence that COMT inhibition results in increased pain
sensitivity comparable to that produced by carrageenan, via β2/3-adrenergic mechanisms. We
previously identified polymorphisms in the COMT gene that are associated with low COMT
enzymatic activity and TMJD onset (Diatchenko et al. 2005). Here, we report the mechanism
whereby low levels of COMT lead to exacerbated pain states. Elevated levels of norepinephrine
and epinephrine, resulting from depressed COMT activity, activate β2/3ARs to produce
heightened pain sensitivity. These findings have important clinical implications, suggesting
that β2- and β3AR antagonists may benefit patients suffering from pain conditions resulting
from low COMT activity and/or elevated catecholamine levels.
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COMT inhibition produces tactile allodynia, mechanical hyperalgesia, and thermal
hyperalgesia. Administration of the COMT inhibitors OR486 (30 mg/kg) or RO41-0960 (30
mg/kg) (A) decreased paw withdrawal threshold to mechanical stimuli (4.04 ± 0.32 g and 8.01
± 0.56 g for animals receiving OR486 and RO41-0960, respectively, relative to controls with
a paw withdrawal threshold of 20.76 ± 0.37 g), (B) increased paw withdrawal frequency to
repeated presentation of a 25 g monofilament (46.56 ± 2.82 % and 22.81 ± 2.33 % for animals
receiving OR486 and RO41-0960, respectively, relative to controls with a paw withdrawal
frequency of 7.97 ± 1.10 %), and (C) decreased paw withdrawal latency to thermal stimuli
relative to vehicle (5.09 ± 0.24 s and 6.56 ± 0.25 s for animals receiving OR486 and RO41-0960,
respectively, compared to controls with a paw withdrawal latency of 7.92 ± 0.25 s). Animals
receiving OR486 (30 mg/kg) + saline or vehicle + carrageenan (3%) produced a similar degree
of (D) tactile allodynia and (E) mechanical hyperalgesia relative to those receiving vehicle +
saline. Furthermore, administration of OR486 + carrageenan produced an additive effect on
behavioral responsiveness to mechanical stimuli relative to those receiving either vehicle +
carrageenan or OR486 + saline (panel D and E insets). (F) Animals receiving OR486 + saline,
vehicle + carrageenan, or OR486 + carrageenan also produced a similar degree of thermal
hyperalgesia relative to those receiving vehicle + saline. N = 8 per group. Data are Mean ±
SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (A–C) or vehicle + saline
(D–F). #P < 0.05 different from vehicle + carrageenan and OR486 + saline.
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Administration of the nonselective βAR antagonist propranolol completely blocks OR486-
induced pain sensitivity. Administration of propranolol (3 mg/kg) prior to OR486 (30 mg/kg)
normalized (A) paw withdrawal threshold to mechanical stimuli, (B) paw withdrawal
frequency to a noxious punctate stimulus, and (C) paw withdrawal latency to radiant heat
relative to animals receiving the α-adrenergic antagonist phentolamine (3 mg/kg), D1-like
dopamine antagonist SCH23390 (0.2 mg/kg), D2-like dopamine antagonist spiperone (0.2 mg/
kg), or vehicle prior to OR486. Administration of phentolamine, propranolol, SCH23390, or
spiperone 10 min prior to i.p. administration of vehicle failed to affect (D) paw withdrawal
threshold to mechanical stimuli, (E) paw withdrawal frequency to a noxious punctate stimulus,
or (F) paw withdrawal latency to radiant heat relative to vehicle. N = 8 per group. Data are
Mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle + OR486.
Nackley-Neely et al. Page 14














Administration of selective antagonists for β2- or β3ARs reduces OR486-induced pain
sensitivity. Administration of the middle (0.5 mg/kg) or high (5.0 mg/kg) dose of the β2
antagonist ICI118,551 prior to OR486 (30 mg/kg) (A) increased paw withdrawal threshold and
(B) decreased paw withdrawal frequency to a noxious punctate stimulus relative to animals
receiving vehicle or the low (0.05 mg/kg) dose of ICI118,551. (C) Administration of the high
dose of ICI118,551 also increased paw withdrawal latency to radiant heat relative to animals
receiving vehicle prior to OR486. Administration of the middle (5 mg/kg) or high (50 mg/kg)
dose of the β3 antagonist SR59230A prior to OR486 (30 mg/kg) (D) increased paw withdrawal
threshold to mechanical stimuli, (E) decreased paw withdrawal frequency to a noxious punctate
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stimulus, and (F) increased paw withdrawal latency to thermal stimuli relative to animals
receiving vehicle. (G–I) Administration of the β1AR antagonist betaxolol (0.1, 1.0, or 10 mg/
kg) prior to OR486 failed to alter pain sensitivity. Administration of ICI118,551, SR59230A,
or betaxolol 10 min prior to i.p. administration of vehicle failed to affect (J) paw withdrawal
threshold to mechanical stimuli, (K) paw withdrawal frequency to a noxious punctate stimulus,
or (L) paw withdrawal latency to radiant heat relative to vehicle. N = 8 per group. Data are
expressed as Mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle +
vehicle. +++P < 0.001, ++P < 0.01, +P < 0.05 different from vehicle + OR486.
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Coadministration of selective antagonists for β2- and β3ARs completely blocks OR486-
induced pain sensitivity. Concurrent administration of ICI118,551 (0.5 mg/kg) and SR59230A
(5.0 mg/kg) prior to OR486 (30 mg/kg) completely normalized (A) paw withdrawal threshold
to mechanical stimuli, (B) paw withdrawal frequency to a noxious punctate stimulus, and
(C) paw withdrawal latency to radiant heat. N = 8 per group. Data are expressed as Mean ±
SEM. ***P < 0.001, **P < 0.01 different from vehicle + OR486.
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